Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glioma A New Therapeutic Area Of Interest For GW Pharma

Executive Summary

GW Pharmaceuticals has identified oncology as a potential new therapeutic area for its cannabinoid-based products, but such research is at an early stage and the UK company is currently focused on orphan neurology indications and the setting up commercial operations in the US and Europe.

You may also be interested in...



Deal Watch: Teva's Sol Barer Leads Buyout Of IO Start-up NexImmune

Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.

Dravet Syndrome Indication Will Set GW Pharma Apart On US Epilepsy Market

GW Pharma is on track for 2017 filings for its marijuana-derived epilepsy therapy, Epidiolex (cannabidiol), following more positive data from the third Phase III study for the drug to be presented this year – however, Epidiolex's potential in Dravet syndrome will be its competitive edge to set GW apart from rivals.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC098205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel